Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: A systematic review and meta-analysis

Europace

Volumn 15, Issue 10, 2013, Pages 1412-1420

  Bin Abdulhak, Aref A ^a   Khan, Abdur Rahman ^b   Tleyjeh, Imad M ^c,d   Spertus, John A ^a,e   Sanders, Susan U ^e   Steigerwalt, Kristy E ^e   Garbati, Musa A ^c   Bahmaid, Reem A ^f   Wimmer, Alan P ^a,e  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

^c KING FAHAD MEDICAL CITY   (Saudi Arabia)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^f NONE   (Saudi Arabia)

Author keywords

Atrial fibrillation; Catheter ablation; Dabigatran; Warfarin

Indexed keywords

DABIGATRAN; WARFARIN;

ANTICOAGULANT THERAPY; ATAXIC APHASIA; BLEEDING; BLOOD CLOTTING TIME; BRAIN INFARCTION; CARDIOVASCULAR RISK; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CRYOABLATION; DRUG EFFICACY; DRUG SAFETY; ELECTROCOAGULATION; HEART ATRIUM FIBRILLATION; HUMAN; LUNG EMBOLISM; MEDIAL LONGITUDINAL FASCICULUS; META ANALYSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RADIOFREQUENCY ABLATION; REVIEW; SENSITIVITY ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOEMBOLISM; WEAKNESS;

ATRIAL FIBRILLATION; CATHETER ABLATION; DABIGATRAN; WARFARIN;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; CATHETER ABLATION; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; HEMORRHAGE; HUMANS; ODDS RATIO; PYRIDINES; RISK FACTORS; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN;

EID: 84884997616     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut239     Document Type: Review

References (33)

1. Knight BP. Anticoagulation for atrial fibrillation ablation: what is the optimal strategy? J Am Coll Cardiol 2012;59:1175-7.
2. Konduru SV, Cheema AA, Jones P, Li Y, Ramza B, Wimmer AP. Differences in intraproceduralACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin. J Interv Card Electrophysiol 2012;35:277-84.
3. Dorobantu M, Vatasescu R. Oral anticoagulation during atrial fibrillation ablation: facts and controversies. Cor et Vasa 2013;55:e101-e106.
4. Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 2010;121:2550-6.
5. Hakalahti A, Uusimaa P, Ylitalo K, Raatikainen MJ. Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment. Europace 2011;13: 640-5.
6. Hussein AA, Martin DO, Saliba W, Patel D, Karim S, Batal O et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm 2009;6: 1425-9.
7. Santangeli P, Di Biase L, Sanchez JE, Horton R, Natale A. Atrial fibrillation ablation without interruption of anticoagulation. Cardiol Res Pract 2011;2011:837841.
8. Wazni OM, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation 2007;116:2531-4.
9. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012;14:528-606.
10. Connolly SJ, Pogue J, Eikelboom J, Flaker G,Commerford P, FranzosiMGet al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-37.
11. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-83.
12. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361: 1139-51.
13. Bassiouny M, SalibaW, Rickard J, Shao M, Sey A, Diab M et al. Use of dabigatran for peri-procedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 2013;6:460-6.
14. Imamura K, Yoshida A, Takei A, Fukuzawa K, Kiuchi K, Takami K et al. Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. J Interv Card Electrophysiol 2013. [Epub ahead of print].
15. Kim JS, She F, Jongnarangsin K, ChughA, Latchamsetty R, GhanbariHet al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2013;10:483-9.
16. Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, SwarupVet al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from amulticenter prospective registry. J Am Coll Cardiol 2012;59:1168-74.
17. Snipelisky D, Kauffman C, Prussak K, Johns G, Venkatachalam K, Kusumoto F.Acomparison of bleeding complications post-ablation between warfarin and dabigatran. J Interv Card Electrophysiol 2012;35:29-33.
18. Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M et al. Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation. Clin Drug Investig 2013;33:409-18.
19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339:2700.
20. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12.
21. Wells G, Shea B, O'Connell D, Peterson J,Welch V, Losos M et al. The Newcastle- Ottawa Scale (NOS) for Assessing the Quality of Non-randomized Studies in Meta-analysis. Ottawa, Ontario: The Ottawa Health Research Institute. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp (26 January 2013, date last accessed)
22. Jadad AR, Moore RA, Carroll D, JenkinsonC, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
23. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:1351-75.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ 2003;327:557-60.
25. Khan S, Duggal M, Dunskis P, Bhan A. Periprocedural dabigatran in patients undergoing catheter ablation for atrial fibrillation. J Am Coll Cardiol 2013;61: (10-S) [Abstr]. http://content.onlinejacc.org/article.aspx?Articleid= 1664548 (6 May 2013, date last accessed).
26. Mendoza I, Helguera M, Baez-Escudero J, Reina J, Pinski SL. Atrial fibrillation ablation on uninterrupted anticoagulation with dabigatran versus warfarin. Heart Rhythm 2012;9:S270-1. [Abstr]. http://dx.doi.org/10.1016/j. hrthm.2012.03.033 (6 May 2013, date last accessed).
27. Nin T, Sairaku A, Yoshida Y, Kamiya H, Tatematsu Y, NanasatoMet al.Arandomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol 2013;36: 172-9.
28. Kok LC, Mangrum JM, Haines DE, Mounsey JP. Cerebrovascular complication associated with pulmonary vein ablation. J Cardiovasc Electrophysiol 2002;13:764-7.
29. Cappato R, Calkins H, Chen S, DaviesW, Iesaka Y, Kalman J et al.Worldwide survey on the methods, efficacy and safety of catheter ablation for human atrial fibrillation. Circulation 2005;111:1100-5.
30. Oral H, Chugh A, Ozaydin M, Good E, Fortino J, Sankara S et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 2006;114:759-65.
31. Sanford M, Plosker GL. Dabigatran etexilate. Drugs 2008;68:1699-709.
32. Garnock-Jones KP. Dabigatran etexilate. A review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Am J Cardiovasc Drugs 2011;11:57-72.
33. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-95.